Business Context and Reporting Period
This Form 8-K filing by Trevi Therapeutics, Inc. (TRVI) is dated March 16, 2022. The report addresses a corporate governance event regarding the company's listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on stock price compliance metrics.
Material Changes
The primary material change reported is the resolution of a listing deficiency:
- Deficiency: On January 10, 2022, the company received a notice from Nasdaq stating its common stock failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days.
- Resolution: On March 16, 2022, the company received a Compliance Letter confirming it regained compliance.
- Compliance Period: The stock maintained a closing bid price of at least $1.00 per share for ten consecutive business days from March 2, 2022, through March 15, 2022.
- Status: Nasdaq has considered the matter closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks. The only contingency mentioned was the potential loss of Nasdaq listing, which has been resolved. The company was originally granted an 180-day period (until July 11, 2022) to regain compliance, which it achieved early.
Investor Verification Checklist
- Verify the current trading price of TRVI to ensure continued compliance with the $1.00 minimum bid price requirement.
- Confirm that no new deficiency letters have been issued by Nasdaq subsequent to March 16, 2022.
- Review the company's most recent 10-K or 10-Q filings for actual financial performance metrics, as this 8-K contains none.